Article Detail - JF Part A
Self-Administered Drug Exclusion List (A53033) - R43 - Effective July 1, 2025
Date Posted: June 26, 2025
This billing and coding article has been revised and published for notice under contract numbers: 02101 (AK), 02201 (ID), 02301(OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).
Effective Date: July 1, 2025
Summary of Changes:
Added: Q5098 Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg*; Q5099 Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg*; and Q5100 Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg*
Revised: Q9998 descriptor from "INJECTION, USTEKINUMAB-AEKN (SELARSDI), 1 MG" to "Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg"
Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.
To view the complete listing of billing and coding articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Billing and Coding Articles webpage.
